Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial
BackgroundTriple negative breast cancer (TNBC) is more prevalent among the younger age group and is the most aggressive form. Women with TNBC phenotype have 19% lower 5-year overall survival and 18% lower disease-free survival than their non-TNBC counterparts (1). Hence, extensive research is essent...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1561692/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|